NCT03524157View on ClinicalTrials.gov

Safety and Tolerability of PRO-087 Versus Xyel Ofteno® and Systane Ultra®, on the Ocular Surface of Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 17, 2017

Primary Completion Date

February 12, 2018

Study Completion Date

March 27, 2018

Conditions
Dry Eye SyndromesLubricant AllergyTear Disorder
Interventions
DRUG

PRO-087

The intervention period consists of a therapy with PRO-087administered 4 times a day in the waking period for 10 days. with a security call to day 13.

DRUG

Systane Ultra

The intervention period with active comparator drug consists of a therapy with systane administered 4 times a day in the waking period for 10 days. with a security call to day 13.

DRUG

Xyel Ofteno

The intervention period with active comparator drug consists of a therapy with Xyel administered 4 times a day in the waking period for 10 days. with a security call to day 13.

Trial Locations (1)

45050

Private Ophthalmological Office, Zapopan

All Listed Sponsors
lead

Laboratorios Sophia S.A de C.V.

INDUSTRY

NCT03524157 - Safety and Tolerability of PRO-087 Versus Xyel Ofteno® and Systane Ultra®, on the Ocular Surface of Healthy Subjects | Biotech Hunter | Biotech Hunter